☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Share this
PS Admin
Jun 20, 2024
Clinical Trials
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Click here
to read the full press release
Comments
Fill this Details
×
Name
Email
Company Name
Thank you for download PDF
Submit
Related News/Articles
Tubulis Reports the US FDA’s Fast Track Designation of TUB-040 to Treat Ovarian Cancer
June 28, 2024
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-aa
June 20, 2024
PharmaShots Magazine - November 2024 Edition
November 13, 2024
Bridging the Biopharma Gap with Consulting Firms
November 13, 2024
Flare Therapeutics Inks Pact with Roche to Develop Small Molecules Targeting Undrugged Transcription Factors in Oncology
November 13, 2024
Schrödinger Enters into a Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
November 13, 2024
Balanced Health: How Holistic Practices and Supplements Work Together for Wellness
November 13, 2024
Kalaris Therapeutics Reverse Merges with AlloVir to Advance Therapies Focusing on Retinal Diseases
November 11, 2024
The Role of CCL17 in Immune Regulation: Unlocking New Therapeutic Possibilities
November 8, 2024
Johnson & Johnson MedTech Reports the US FDA’s Approval of VARIPULSE Pulsed Field Ablation Platform to Treat Atrial Fibrillation
November 8, 2024
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
×
Email
First Name
Last Name
Company Name
Area/Designation
Daily Newsletter
Weekly Newsletter
Stay Connected
LinkedIn
Twitter
Facebook
instagram
Youtube
Join the PharmaShots family of 12000+ subscribers
Newsletter
Subscribe Now
I accept the
Terms and Conditions
X
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
Subscribe
Modal title
×
Modal body text goes here.
